Neose Technologies, Inc. (extinct)

Neose Technologies, Inc. (extinct)

Neose Technologies, Inc. (extinct)

Overview
Date Founded

1991

Headquarters

102 Rock Road,Horsham, PA 19044

Type of Company

Private

Employees (Worldwide)

1 - 10

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market.

Executives & Employees

Chief Financial Officer & Senior Vice President

Paths to Neose Technologies, Inc.
Potential Connections via
Relationship Science
You
Neose Technologies, Inc.
Recent Transactions
Details Hidden

Novo Nordisk A/S, BioGeneriX AG purchase Neose Technologies, Inc.

Details Hidden

Neose Technologies, Inc. issued USD Common Stock

Details Hidden

Neose Technologies, Inc. issued USD Common Stock

Transaction Advisors
Auditor

Advised onNeose Technologies, Inc. issued USD Common Stock

Underwriter

Advised onNeose Technologies, Inc. issued USD Common Stock

Underwriter

Advised onNeose Technologies, Inc. issued USD Common Stock

Investments
Details Hidden

Novazyme Pharmaceuticals, Inc. researches and develops methods for modifying recombinantly produced enzymes. It develops a series of novel protein engineering technologies that have been shown in pre-clinical studies to greatly enhance the targeting and uptake of replacement enzymes. Novazyme's technologies also have application for developing advanced monoclonal antibodies and gene therapies. The company is located in Oklahoma City, OK.

Details Hidden

Garnet BioTherapeutics, Inc. develops products that speed healing and reduce scarring after surgery or dermatologic procedures. It is a clinical stage regenerative medicine company that discovers, develops, and delivers new regenerative therapies by leveraging the intrinsic ability of adult somatic cells to repair, regenerate, and remodel tissue in acute and chronic disease settings. The firm's manufacturing and technology platform is a scalable GMP-compliant manufacturing process that can be applied to multiple cell types including adult bone marrow-derived stromal cells, smooth and skeletal muscle cells, dermal fibroblasts, chondrocytes, pre-adipocytes, and endothelial cells. The company was founded by Hubert J.P. Schoemaker on November 26, 2003 and is headquartered in Malvern, PA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Neose Technologies, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Neose Technologies, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Neose Technologies, Inc..